EUVIMEDEUVIMED entdecken
Multizentrische Studie

Systemic JIA‐Associated Lung Disease: A Multicenter Analysis of Clinical Features, Treatment Challenges, and Outcomes

Dilara Unal, Veysel Cam, Elif Kilic Konte, Elif Celikel iD, Semanur Ozdel iD, Metin Kaya Gurgoze, Erdal Sag, Ozge Basaran, Kenan Barut, Berna Oguz, Yelda Bilginer, Ozgur Kasapçopur und 2 weitere

Pediatric Pulmonology · 2026-06 · 61 (6)

DOI: 10.1002/ppul.71690 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Pulmonology, online erschienen am 09.06.2026. Verfasst von Dilara Unal und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Lung Diseases, Arthritis, Juvenile. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic juvenile idiopathic arthritis (sJIA) (Still's disease) associated lung disease (sJIA‐LD) is a rare but severe complication, characterized by pulmonary involvement with high morbidity and mortality rates. While the incidence of sJIA‐LD has increased, its pathogenesis and risk factors remain poorly understood.

Objectives

This multicenter retrospective study aimed to evaluate the clinical, radiological, and laboratory features of patients with sJIA‐LD, assess the impact of prior biologic treatments, and analyze treatment outcomes.

Methods

Data were collected from 18 patients diagnosed with sJIA‐LD between 2007 and 2024 across five pediatric rheumatology clinics in our country. Clinical features, imaging findings, and treatment regimens before and after sJIA‐LD diagnosis were analyzed. HLA‐DRB1*15 typing was performed in a subset of patients.

Results

The median age of sJIA‐LD diagnosis was 11.21 years, with a median disease duration of 2.76 years from sJIA diagnosis. Macrophage activation syndrome (MAS) occurred in 88.9% of patients prior to the diagnosis of lung disease. Cough (100%), dyspnea (83.3%), and clubbing (50%) were the most common clinical manifestations. Ground‐glass opacities were the most frequent imaging finding (61.1%). DRESS was observed in 11.1% of patients, with 27.7% experiencing adverse reactions to biologics. Treatment revision after sJIA‐LD diagnosis occurred in 83.3% of patients, with JAK inhibitors demonstrating clinical improvement in some cases. The overall survival rate was 94.4%, with one death due to fulminant MAS.

Conclusion

This study provides data from a geographically underreported population in Turkey and the Eastern Mediterranean region. In our cohort, treatment modification after sJIA‐LD diagnosis was common, while biologic therapy was often continued. These findings highlight the heterogeneous course of sJIA‐LD. Further prospective multicenter studies are needed to optimize treatment strategies and improve risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung DiseasesArthritis, JuvenileHumansFemaleRetrospective StudiesMaleChildAdolescentMacrophage Activation SyndromeTreatment OutcomeChild, Preschool

Stichwörter der Autor:innen

lung diseasemacrophage Activation Syndromestill's disease

Autor:innen und Institutionen

  • Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey.
  • Department of Pediatric Rheumatology, Cerrahpaşa Faculty of Medicine, İstanbul University, İstanbul, Turkey.
  • Department of Pediatric Rheumatology, Ankara City Hospital, Ankara, Turkey.
  • Department of Pediatric Rheumatology, Ankara Etlik City Hospital, Ankara, Turkey.
  • Department of Pediatric Rheumatology, Fırat University, Elazığ, Turkey.
  • Department of Radiology, Hacettepe University, Ankara, Turkey.

ORCID-Profile: Elif Celikel, Semanur Ozdel

Zitieren

APA

Unal, D., Cam, V., Konte, E. K., Celikel, E., Ozdel, S., Gurgoze, M. K., Sag, E., Basaran, O., Barut, K., Oguz, B., Bilginer, Y., Kasapçopur, O., Dogru, D., & Ozen, S. (2026). Systemic JIA‐Associated Lung Disease: A Multicenter Analysis of Clinical Features, Treatment Challenges, and Outcomes. Pediatric Pulmonology, 61(6). https://doi.org/10.1002/ppul.71690

Vancouver

Unal D, Cam V, Konte EK, Celikel E, Ozdel S, Gurgoze MK, et al. Systemic JIA‐Associated Lung Disease: A Multicenter Analysis of Clinical Features, Treatment Challenges, and Outcomes. Pediatric Pulmonology. 2026;61(6). doi:10.1002/ppul.71690

BibTeX
@article{Unal2026,
  author = {Unal, Dilara and Cam, Veysel and Konte, Elif Kilic and Celikel, Elif and Ozdel, Semanur and Gurgoze, Metin Kaya and Sag, Erdal and Basaran, Ozge and Barut, Kenan and Oguz, Berna and Bilginer, Yelda and Kasapçopur, Ozgur and Dogru, Deniz and Ozen, Seza},
  title = {Systemic JIA‐Associated Lung Disease: A Multicenter Analysis of Clinical Features, Treatment Challenges, and Outcomes},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {6},
  doi = {10.1002/ppul.71690}
}
Kostenlos starten →